Tumor News and Research

RSS

EZH2 protein may aid prognostication in resected NSCLC

A protein called “enhancer of zeste homolog-2” is frequently expressed in non-small-cell lung cancer and may have prognostic value following surgical resection, US researchers believe.

30 Oct 2013

Study suggests neural stem cells have tendency for malignant transformation

Although it is believed that glioma is derived from brain tumor stem cells, the source and molecular signal pathways of these cells are still unclear.

30 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

Janssen submits Marketing Authorization Application for Ibrutinib

Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.

30 Oct 2013

Overweight men diagnosed with prostate cancer more likely to die from the disease

Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published today in the journal Obesity Research & Clinical Practice. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality.

30 Oct 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

Blood levels of microRNAs may serve as diagnostic tool for thyroid cancer, but more research needed

A new analysis has found that the presence of short segments of genetic material (known as microRNA) within papillary thyroid cancer tumors suggests a likelihood of recurrence after patients undergo surgery.

29 Oct 2013

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor.

29 Oct 2013

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

New unique nanostructure to target drug-delivery treatment of cancer cells

A unique nanostructure developed by a team of international researchers, including those at the University of Cincinnati, promises improved all-in-one detection, diagnoses and drug-delivery treatment of cancer cells.

29 Oct 2013

Lipid secreted by tumors inhibits immune response against cancer

Researchers at National Jewish Health have discovered how a lipid secreted by cancer tumors prevents the immune system from mounting an immune response against it. When lysophosphatidic acid binds to killer T cells, it acts almost like an "invisibility cloak," preventing T cells from recognizing and attacking nascent tumors.

29 Oct 2013

Study reveals that specific protein may assist breast cancer cells in metastasizing

A new study by University of Kentucky Markey Cancer Center researchers Min Chen and Kathleen O'Connor shows that a specific protein may assist breast cancer cells in metastasizing.

29 Oct 2013

Complement protein holds diagnostic, prognostic promise in lung cancer

A complement activation product known as “C4d” may have value as a diagnostic and prognostic biomarker for lung cancer, research suggests.

28 Oct 2013

Current drugs may harbor small-cell lung cancer promise

Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease.

28 Oct 2013

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Starting with a combination of three traditional disease-modifying antirheumatic drugs (called DMARDs) for treating early rheumatoid arthritis is more cost-effective long term, with comparable benefits, than using either an immediate or step-up approach with anti-tumor necrosis factor (called Anti-TNFs) drugs and methotrexate, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Study confirms the "seed and soil" theory of metastasis

Oncologists have long puzzled over the fact that after cancer treatment, single cancer cells that are dispersed throughout the body - so-called disseminated tumor cells - are quick to grow and form secondary tumors called metastases in certain organs, while in other organs they metastasize more slowly, sometimes decades later. Such is the case with head and neck squamous cell carcinoma cells, which remain dormant when lodged in bone marrow but rapidly form tumors when they make their way into the lungs.

28 Oct 2013

Two related genes underlie development of two rare bone tumours in nearly 100% of patients

Scientists have made a rare discovery that allows them to attribute two types of tumour almost entirely to specific mutations that lie in two related genes.

28 Oct 2013

Tumor News and Research

EZH2 protein may aid prognostication in resected NSCLC

Study suggests neural stem cells have tendency for malignant transformation

Immune Design closes Series C financing totalling up to $49M

Janssen submits Marketing Authorization Application for Ibrutinib

Overweight men diagnosed with prostate cancer more likely to die from the disease

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

Blood levels of microRNAs may serve as diagnostic tool for thyroid cancer, but more research needed

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

Cytrx announces Q3 2013 financial results, provides clinical update

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New unique nanostructure to target drug-delivery treatment of cancer cells

Lipid secreted by tumors inhibits immune response against cancer

Study reveals that specific protein may assist breast cancer cells in metastasizing

Complement protein holds diagnostic, prognostic promise in lung cancer

Current drugs may harbor small-cell lung cancer promise

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Study confirms the "seed and soil" theory of metastasis

Two related genes underlie development of two rare bone tumours in nearly 100% of patients

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News